Maarja Pajusalu

Maarja Pajusalu

Auto-generated profile, based on publicly available information

Maarja Pajusalu

Institute of Computer Science, University of Tartu, Estonia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
MPMaarja Pajusalu
Maarja Pajusalu
KMKerli Mooses
Kerli Mooses
MOMarek Oja
Marek Oja
STSirli Tamm
Sirli Tamm
MHMarkus Haug
Markus Haug
RKRaivo Kolde
Raivo Kolde

1 May 2024 in Preventive Medicine
Verified
Journal Article
Open access
KMKerli Mooses
Kerli Mooses
AŠAleksandra Šavrova
Aleksandra Šavrova
MPMaarja Pajusalu
Maarja Pajusalu
MOMarek Oja
Marek Oja
STSirli Tamm
Sirli Tamm
RKRaivo Kolde
Raivo Kolde
The fight against cervical cancer requires effective screening together with optimal and on-time treatment along the care continuum. We examined the impact of cervical cancer testing and treatment guidelines on testing practices, and follow-up adherence to guidelines. Data from Estonian electronic health records and healthcare provision claims for 50,702 women was used. The annual rates of PAP tests, HPV tests and colposcopies during two guideline periods (2nd version 2012-2014 vs 3rd version 2016-2019) were compared. To assess the adherence to guidelines, the subjects were classified as adherent, over- or undertested based on the timing of the appropriate follow-up test. The number of PAP tests decreased and HPV tests increased during the 3rd guideline period (p < 0.01). During the 3rd guideline period, among 21-29-year-old women, the adherence to guidelines ranged from 38.7% (44.4…50.1) for ASC-US to 73.4% (62.6…84.3) for HSIL and among 30-59-year-old from 49.0% (45.9…52.2) for ASC-US to 65.7% (58.8…72.7) for ASCH. The highest rate of undertested women was for ASC-US (21-29y: 25.7%; 30-59y: 21.9%). The rates of over-tested women remained below 12% for all cervical pathologies observed. There were 55.2% (95% CI 49.7…60.8) of 21-24-year-olds and 57.1% (95% CI 53.6…60.6) of 25-29-year-old women who received HPV test not adherent to guidelines. Our findings highlighted some shortcomings in guideline adherence, especially among women under 30. The insights gained from this study help to improve the quality of care and, thus, reduce cervical cancer incidence and mortality.

16 February 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MOMarek Oja
Marek Oja
STSirli Tamm
Sirli Tamm
KMKerli Mooses
Kerli Mooses
MPMaarja Pajusalu
Maarja Pajusalu
HTHarry-Anton Talvik
Harry-Anton Talvik
SRSulev Reisberg
Sulev Reisberg
Objective: To describe the reusable transformation process of electronic health records (EHR), claims, and prescriptions data into Observational Medical Outcome Partnership (OMOP) common data model (CDM), together with challenges faced and solutions implemented. Materials and Methods: We used Estonian national health databases that store almost all residents' claims, prescriptions, and EHR records. To develop and demonstrate the transformation process of Estonian health data to OMOP CDM, we used a 10% random sample of the Estonian population (n = 150,824 patients) from 2012-2019. For the sample, complete information from all three databases was converted to OMOP CDM version 5.3. The validation was performed using open-source tools. Results: In total, we transformed over 100 million entries to standard concepts using standard OMOP vocabularies with the average mapping rate 95%. For conditions, observations, drugs, and measurements, the mapping rate was over 90%. In most cases, SNOMED Clinical Terms were used as the target vocabulary. Discussion: During the transformation process, we encountered several challenges, which are described in detail with concrete examples and solutions. Conclusion: For a representative 10% random sample, we successfully transferred complete records from three national health databases to OMOP CDM and created a reusable transformation process. Our work helps future researchers to transform linked databases into OMOP CDM more efficiently, ultimately leading to better real-world evidence.

12 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KMKerli Mooses
Kerli Mooses
MOMarek Oja
Marek Oja
MMMaria Malk
Maria Malk
HLHelene Loorents
Helene Loorents
MPMaarja Pajusalu
Maarja Pajusalu
RKRaivo Kolde
Raivo Kolde
The current knowledge about medication adherence (MA) is based on studies focusing only on few health conditions. We utilised a representative dataset with electronic health records, claims, and prescribed medications to 1) evaluate the effect of multiple factors affecting MA in a consistent manner across 137 ingredients, and 2) calculate individual medication adherence score (IMAS), evaluate its predictive power, stability over time, and impact on health outcomes. The MA ranged from 0.423 (albuterol, 95% CI 0.414–0.432) to 0.922 (warfarin, 95% CI 0.917–0.926). The demographic, health- and medication-related factors explained 11.6% and IMAS 22% of the variation in adherence. IMAS predicted adherence across medication classes, reduced the risk of overall hospitalisation (Hazard ratio = 0.76, 95% CI 0.60–0.97, p<0.05) and cause-specific incidence for 17 conditions. Thus, medication-taking behaviour represents a broader patient-level phenomenon manifesting consistently across medications, suggesting its potential for personalised interventions in clinical practice and more efficient public health strategies and policies.

6 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MPMaarja Pajusalu
Maarja Pajusalu
MOMarek Oja
Marek Oja
KMKerli Mooses
Kerli Mooses
SHSilver Heinsar
Silver Heinsar
OAOliver Aasmets
Oliver Aasmets
RKRaivo Kolde
Raivo Kolde
Characterizing study sample representativeness is critical for the validity of biobank-derived findings, yet selection biases are rarely quantified across the full clinical spectrum. Here we systematically evaluate the Estonian Biobank (EstBB) - comprising ∼20% of the adult population - by comparing two recruitment waves against a 30% national reference dataset (Est-Health-30). Analyzing prevalence ratios (PR) across 1,028 ICD-10 categories, we reveal a bifurcated landscape of representativeness. While EstBB achieves population parity (PR ∼ 1.0) for widespread chronic conditions like Type 2 diabetes, 47% of diagnostic categories exhibit significant deviations (>1.3-fold). We identify a distinct “managed symptomatic” phenotype: a systematic enrichment of outpatient diagnoses - such as melanocytic nevi (PR=2.07, 95% CI 1.93…2.21) and major depression (PR=1.53, 1.4…1.66) - coupled with a depletion of high-mortality conditions like lung cancer (PR=0.69, 0.64…0.75) and vascular dementia (PR=0.45, 0.38…0.54). These biases evolved across recruitment phases, with the later EstBB2 cohort exhibiting a healthier, prevention-oriented profile. To support research integrity, we provide an interactive open-access dashboard for phenotype refinement. Accounting for such selection-driven “clinical visibility” is essential to avoid collider bias in risk prediction and causal inference models.

5 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MPMaarja Pajusalu
Maarja Pajusalu
MOMarek Oja
Marek Oja
KMKerli Mooses
Kerli Mooses
SHSilver Heinsar
Silver Heinsar
TLTriin Laisk
Triin Laisk
RKRaivo Kolde
Raivo Kolde
Health research increasingly relies on observational datasets that capture systematically different patient populations, affecting the representativeness, comparability, and transportability of study findings. Yet these differences are rarely quantified across clinical domains or explored interactively, and the workflow for pairwise dataset comparison remains fragmented. We present Syrona, a visual analytics workflow for systematic pairwise comparison of datasets and subcohorts on the OMOP Common Data Model. Syrona extracts annual prevalence for conditions, procedures, and drugs from any OMOP CDM database, computes prevalence ratios across demographic strata, and synthesizes them via multilevel meta-analysis. A coordinated dashboard - distributional overviews, stratified heatmaps, forest plots, and absolute prevalence comparisons - enables interactive exploration driven by domain-adaptive SNOMED CT and ATC filtering. Three case studies on Estonian national health data (495,000 persons, 2012-2024) demonstrate how the workflow supports representativeness assessment, institutional practice comparison, and coding artifact detection. Syrona is open-source and applicable to any OMOP CDM database. Explore the demo at: http://omop-apps.cloud.ut.ee/ShinyApps/Syrona/